Tasrif Pharmaceutical is a biotech startup company founded in 2018. Tasrif Pharmaceutical’s focus is on aviral targeting of the poliovirus receptor (aka CD155). The poliovirus receptor (PVR) is overexpressed on numerous malignancies and PVR-TIGIT interaction has been identified as a novel checkpoint.
Tasrif Pharmaceutical’s lead molecule, TSRF 786C, is a hinge stabilized (S241P) IgG4 fully humanized monoclonal antibody against PVR. The USPTO has granted a patent for TSRF 786C and related antibodies and antibody fragments and their respective drug conjugates for the treatment of cancer.
Tasrif Pharmaceutical is a preclinical stage company and none of the products are FDA approved.
Human U87 tumors accumulate Anti-PVR antibodies in Mice.